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Abstract
Background: There is no clear and contemporaneous method for screening of idiopathic hirsutism (IH) and
polycystic ovary syndrome (PCOS) at the community level and current estimates regarding their prevalence are
limited. We aimed to ascertain the prevalence of IH and PCOS in a randomly selected sample of reproductive aged
female participants of the Tehran Lipid and Glucose Study (TLGS).
Methods: One thousand and two women, aged 18-45 years, were randomly selected from among reproductive
aged women who participated in the TLGS. Those women with either hirsutism or menstrual dysfunction were
assessed for biochemical hyperandrogenemia; whereas those participants with hirsutism per se were further
assessed for subclinical menstrual dysfunction. PCOS were diagnosed using the National Institute of Health (NIH)
criteria. IH was defined as hirsutism without clinical or sub clinical menstrual dysfunction or biochemical
hyperandrogenemia (BH).
Results: The mean ± SD of age of study population was 29.2 ± 8.7 years. Estimated prevalences of idiopathic
hirsutism and pure menstrual dysfunction were 13.0% (95% CI: 10.9%-15.1%) and 1.5%(95% CI: 1.1%-1.9%),
respectively. The prevalence of PCOS was 8.5% (95% CI: 6.8% - 10.2%); more than one third of these cases would
possibly have remained undiagnosed or misdiagnosed, had we not assessed them for subclinical menstrual
dysfunction or biochemical hyperandrogenemia.
Conclusions: These data from a large representative and non selected population of women confirm the concept
that IH and PCOS are the two most common gynecological endocrinopathies among reproductive aged women.
The estimated prevalence of these conditions is highly influenced by their screening methods at the community
level.
Keywords: Prevalence, Polycystic Ovary Syndrome (PCOS), NIH criteria, Tehran Lipid and Glucose Study (TLGS), Idio-
pathic Hirsutism (IH)
Background
Hirsutism, the presence of terminal hairs in females in a
male-like pattern, affects between 5% and 10% of
women and is considered as idiopathic hirsutism (IH)
with the presence of hirsutism and the absence of ano-
vulation and/or hyperandrogenemia [1]. The definition
of IH has varied significantly over the past three dec-
ades, along with changes in the definition of polycystic
ovary syndrome (PCOS), however as IH is a diagnosis of
exclusion, it is often difficult to fully differentiate these
two disorders [2]. There are only a few community
based studies documented that have estimated the pre-
valence of these two conditions [3-5].
The reported prevalence range of PCOS is between
2.2% to 26% [3,5-14] and it is estimated that approxi-
mately 5% to 20% of hirsute patients will have IH
[1,2,15-17]. PCOS is a heterogeneous disorder and its
influence on reproductive capability and metabolic dis-
turbances including insulin resistance, type 2 diabetes
mellitus, dyslipidemia and cardiovascular diseases is
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recruitment of study subjects [18-22]; furthermore the
metabolic and cardiovascular complications of IH have
not been appropriately described [1,23].
Ethnic and racial variations strongly affect the clinical
presentation of PCOS and IH [24-27]; the wide ranges
of prevalence of these disorders can be further explained
by differences in the recruitment process of the study
population, controversy regarding its diagnostic criteria
and the method used to define each criteria. The type of
participants in each epidemiological study may poten-
tially bias the result [12]; using the Rotterdam (Rott.)
versus the NIH criteria, increases the PCOS prevalence
by 1.5-2 times and undoubtedly this reduces the preva-
lence of IH [5,28-30].
Furthermore, relying only on clinical assessment for
identification of hyperandrogenemia or menstrual dys-
function can easily overlook sub clinical oligo anovula-
tion or hyperandrogenemia [16,31,32].
We aimed to identify the prevalence and clinical char-
acteristics of PCOS and IH among a non-selected sam-
ple of reproductive aged women who participated in the
TLGS.
Methods
Study subjects and the sampling method
The subjects of the present study were selected from the
Tehran Lipid and Glucose Study (TLGS) [33]. TLGS is
an ongoing prospective study in Tehran with the aim of
determining the prevalence of non communicable disease
risk factors; 15005 people aged 3 years and above, were
selected from a geographically defined population using
multistage cluster sampling method. There were 4290
women, aged 18-45 years who participated in TLGS;
each woman was ranked according to a specific TLGS
code, according to which, 1060 subjects were randomly
selected using systematic random sampling method. We
included all women regardless of hormonal therapy,
including oral contraceptive pills or continuous proges-
tin, glucocorticoid, or insulin sensitizer or anti androgen
therapy. This is important because PCOS may predispose
patients to the use of hormonal therapy and we would
have underestimated the PCOS prevalence, had we not
included these women. Menopausal women, those who
had undergone hysterectomy or bilateral oophorectomy
and pregnant women were excluded (n = 58).
A standard questionnaire including demographic vari-
ables and reproductive history, with emphasis on regu-
larity of menstrual cycle, gynecological history,
hyperandrogenic symptoms, family history of irregular
menstrual cycle and hirsutism was completed, during
face-to-face interviews and hirsutism was assessed using
the modified Ferriman-Gallwey (mFG) scoring
method [30] by a general practitioner who had been
trained in a one month observer course at the PCOS
clinic under supervision of a single endocrinologist (H.
R.). Patients on hormonal therapy were questioned
regarding their menstrual cy c l i c i t yb e f o r et h e ys t a r t e d
the medications and their hormonal assessment was
excluded in the statistical analysis. Subjects with acne
and or an initial mF-G score of over 3 and/or menstrual
dysfunction defined as vaginal bleeding episodes at no
less than 35-day intervals [32,33] were re-assessed by a
single endocrinologist (H.R.).
An overnight fasting venous blood sample was
obtained from those subjects with hirsutism defined as
mFG >= 8/or menstrual dysfunction on the second or
third day of their spontaneous or progesterone induced
menstrual cycles (n = 260). In women with hirsutism
only, serum was obtained on any one day between days
22-24 of the cycle for the measurement of progesterone
(P4) to confirm ovulatory function (P4 level < 4 ng/ml,
indicating anovulation). All sera were stored at -80°C
until the time of measurements.
Measurements
Dehydroepiandrosterone sulfate (DHEAS), 17-hydroxy-
progesterone (17OH-P), Total testosterone (TT) and
androstendion(A4) were measured by enzyme immu-
noassay (EIA), (Diagnostic biochem canada Co. Ontario,
Canada). Sex Hormone Binding Globulin (SHBG) was
measured by immunoenzymometric assay (IEMA),
(Mercodia, Uppsala, Sweden). All ELISA tests were per-
formed using the Sunrise ELISA reader (Tecan Co. Salz-
burg, Austria).
Luteinizing hormone (LH), Follicle stimulating hor-
mone (FSH), Prolactin (PRL), and Thyroid stimulating
hormone (TSH) were measured by the immunoradi-
metric assay (IRMA), (Izotop, Budapest, Hungary) using
gamma counter(Wallac Wizard, Turku, Finland).
The free androgen index (FAI) was calculated using
the formula [TT (nmol/L) × 100/SHBG (nmol/L)].
Intra-and inter-assay coefficients of variation for TT
were 3.6% and 6.0%; for DHEAS: 1.9% and 3.2%; for 17
OH-P: 5.1% and 6.2%; for SHBG: 1.1% and 4.1%; for A4:
2.2% and 3.5%; for LH-2.8% and 5.6%; for FSH: 3.5%
and 3.9%; for TSH: 1.9% 3.4%, and for PRL, they were
2.1% and 4.3%.
Definitions
Clinical hyperandrogenism (CH) was defined by the pre-
sence of hirsutism (mF-G ≥8) [30], acne, or the presence
of androgenic alopecia [2]. Clinical menstrual dysfunc-
tion was considered as vaginal bleeding episodes at no
less than 35-day intervals [34,35] and sub-clinical men-
strual dysfunction was defined as the presence of oligo-
anovulation in eumenorrheic women (cycles 27-34 days
in length). Oligo-anovulation was determined by
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between days 20 to 24 of the cycle. If progesterone level
was below 4 ng/mL, and the result was repeated in one
more cycle, then the cycle was considered to be oligo-
anovulatory [2]. Biochemical hyperandrogenemia (BH)
was detected by FAI and/or DHEAS and/or A4 level,
above the upper 95th percentile for the 40 women stu-
died, who were not on any hormonal medication and
had no clinical evidence of hyperandrogenism and men-
strual dysfunction (total T = 0.89 ng/ml, A4 = 2.9 ng/
ml, DHEAS = 179 μg/dL and FAI = 5.39). HA was
determined as clinical hyperandrogenism (CH) and/or
biochemical hyperandrogenemia (BH). Idiopathic hirsut-
ism (IH) was defined as hirsutism without menstrual
dysfunction and BH. PCOS was defined using NIH cri-
teria as the combination of menstrual dysfunction and
clinical hyperandrogenism and/or hyperandrogenemia
(HA), after excluding hyperprolactinemia, thyroid dys-
function, nonclassic 21-hydroxylase deficiency (NC-
CAH) and Cushing’s syndrome.
Statistical analysis
Continuous variables, checked for normality, using the
one-sample Kolmogorov-Smirnoff test, are expressed as
mean ± standard deviation and/or median and inter-
quartile ranges, as appropriate. The categorical variables,
expressed as percentages, were compared using the x
2
test. Distributions between groups were compared using
the Kruskal-Wallis test, followed by Mann-Whitney test
with Bonferroni correction for pair wise comparison.
Data analysis was performed using the SPSS 15.0 PC
package (SPSS Inc., Chicago, IL).
Details of Ethics Approval
The ethical review board of the Research Institute for
Endocrine Sciences has approved the study proposal and
informed consent was obtained from all subjects.
Results
The study procedure is summarized in Figure 1. A sam-
ple of 1060 women was randomly selected from among
4290 women, aged 18-45 years, who participated in
TLGS. The mean age of study population was 29.2 years
(age range: 18-45 years). Of the 1002 eligible women
included in the study, 30.0% were overweight (BMI,
25.0-29.9 kg/m
2), and 20.5% were obese (BMI≥30.0 kg/
m
2).
Of a total of 1002 women, 718 women were found to
have no hirsutism or clinical menstrual dysfunction
based on their history and physical examination; they
were not further evaluated and considered as normal
eumenorrheic non hirsute women. Of 256 women with
hirsutism, 246 ones completed the study procedure, of
these 246, 43 women (4.3%) had both BH and CH,
without PCOS and 130 had IH; the estimated prevalence
was 13.0% (95% CI: 10.9%-15.1%). The prevalence of
subclinical menstrual dysfunction among women with
hirsutism was 11.3%(22/195). There were three cases of
acne-per se but all of them had biochemical hyperan-
drogenemia. Of 78 women with clinical menstrual dys-
function who completed the study procedure, 15
subjects had menstrual dysfunction per se, while the
prevalence of BH among non hirsute women with men-
strual dysfunction was 44.4% (12/27); there were no sig-
nificant differences in reproductive history and results of
the first assessment for androgen excess symptoms
between those who completed the study and those who
did not (data was not shown).
The estimated prevalence of PCOS was 8.5%(95% CI:
6.8%-10.2%) using the NIH definition. Of the 85
women with PCOS, 51 had both clinical hirsutism and
menstrual dysfunction. There were 12 PCOS women
with only clinical hirsutism and 22 women with clini-
cal menstrual dysfunction per se and both groups
would possibly have remained undiagnosed, had we
n o ta s s e s s e de i t h e rt h es e r u mc o n c e n t r a t i o n so fa n d r o -
gens in non hirsute women with menstrual dysfunction
or the mid luteal phase of progesterone of hirsute
women.
Out of 21 women with a screening 17-OHP levels >6
nmol/L, there was one subject with NCCAH using the
17-HP response to ACTH stimulation test. Of twenty
women who had features suggestive of Cushing’ss y n -
drome, one had a positive overnight low dose Dexa-
methasone suppression test. No suspicious case of an
androgen secreting tumor was seen among study
participants.
The basic, reproductive, metabolic and hormonal pro-
f i l e so ft h o s ew h oh a dv a r i o u sp h e n o t y p e so fm e n s t r u a l
dysfunction and androgen excess disorders in compari-
son to normal women are shown in table 1. Compared
to healthy subjects, the familial history of hirsutism was
more prevalent among all other phenotypes but only
women with IH had a significant higher BMI in compar-
ison to the normal group. While serum concentrations
of TT did not differ in women with the menstrual dys-
function per se in comparison to PCOS participants,
their SHBG was significantly higher than the latter
(Table 1).
Discussion
The present study demonstrated that the prevalences of
IH and PCOS (using the NIH definition) in a sample of
reproductive aged women who participated in Tehran
Lipid and Glucose Study were 13.0% (95% CI: 10.9%-
15.1%) and 8.5%(95% CI: 6.8%-10.2%), respectively.
More than one third of affected women (34/85) would
have been possibly misclassified, had we not assessed
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biochemical hyperandrogenemia.
In spite of the potential public health impact of the
PCOS there are relatively few studies that estimate its
prevalence at the community levels and most studies
available have relied upon convenience samples
[3,11-13] that potentially bias their results. The reported
prevalence range of PCOS is between 2.2% to 26%
[3,5-13]. In addition to different recruitment processes
of the study population, selection bias, ethnic and racial
variation, the wide range of estimated PCOS prevalence
can be explained by the criteria used for its definition
Figure 1 Summary of study procedure. CH, clinical hyperandrogenism; C-menstrual dysfunction, clinical menstrual dysfunction; SC-menstrual
dysfunction; BH, biochemical hyperandrogenemia; IH, idiopathic hirsutism; PCOS, polycystic ovary syndrome using NIH definition; C&BH, clinical
and biochemical hyperandrogenemia; NC-CAH, nonclassic 21-hydroxylase deficiency. *The serum concentration of mid luteal phase progesterone
of 195 out of 205 women was measured.
Tehrani et al. Reproductive Biology and Endocrinology 2011, 9:144
http://www.rbej.com/content/9/1/144
Page 4 of 8and the screening methods used to identify each criteria
[4,6,8,36,37]; considering the Rotterdam versus NIH cri-
teria increase the PCOS prevalence by 2 times
[5,21,28,29,38]. Our study is comparable with those few
community based studies that provide an estimation
regarding the PCOS under NIH criteria [4,5,28]. Similar
to our estimation, the prevalence of PCOS using NIH
definition was reported to be 8.7% among 978 women,
who were recruited in a retrospective birth cohort study
in South Australia [4], however our estimation is much
higher than that implied by Kumarapeli et al in a non
selected population in Sri Lanka [28]; the racial variation
in hyperandrogenic manifestation of PCOS [39,40]and
the lower degree of hirsutism among indigenous Sri
Lankans might explain the difference observed [28].
There is no clear and contemporaneous recognition of
each PCOS criteria; this could highly influence the
PCOS prevalence estimated. In our study, clinical hyper-
androgenism was determined as mF-G ≥8 and men-
strual dysfunction was defined as vaginal bleeding
episodes at no less than 35-day intervals or P4 level < 4
ng/ml in the mid luteal phase; some other investigators
have used different cut of points for these definitions, e.
g. Asuncion et al. used six or fewer menstrual cycles in
a year as the definition for menstrual dysfunction [3],
the clinical hyperandrogenism was defined as mF-G ≥6
by Knochenhauer et al. [10]and as mF-G ≥7b yD e U -
garte et al. [26].
There is no agreement on widespread screening of
PCOS criteria; it is not clear whether or not biochemical
Table 1 Characteristics of various phenotypes of androgen excess and/or anovulation
Group Group1
(PCOS)
N=8 5
Group 2
menstrual dysfunction
per se
N=1 5
Group 3
(CH+BH)
N=4 3
Group 4
(IH)
N = 130
Group 5
(Normal)
N = 718
Age a 27.0 (21.0-35.0) 29.0 (20.0-34.5) 30.0 (23.0-35.0) 33.0 (26.0-38.0) 29.0 (21.0-36.0)
Age at menarche 13.0 (12.0-13.0) 13.0 (12.5-13.5) 13.0 (13.0-14.0) 13.0 (12.0-14.0) 13.0 (13.0-14.0)
Women with history of primary
Infertility %
b 8.2 5.7 3.7 2.2 1.7
Women with family history of hirsutism
%
b 58.8 39.6 b 40.7 b 49.6 24.9
Women with family history of
anovulation %
b 32.9 30.2 29.6 24.1 17.0
Women with family history of infertility
%
b 9.4 3.8 4.8 2.9 2.9
Women with history of abortion % 14.1 18.9 11.1 17.5 17.3
No. Pregnancy 1.0 (0-2.0) 1 (0-2.0) 0 (0-2) 2.0 (1.0-3.0) 1 (0-2)
BMI (kg/m2) 26.2 (22.3-30.5) 26.2 (22.4-29.2) 24.1 (22.1-27.9) b 26.7 (23.7-29.7) 24.5 (21.2-28.7)
Waist circumference (cm) 85.0 (78.0-98.5) 83.0 (75.5-92.5) 81.0 (74.0-92.0) 88.0 (79.5-98.5) 82.0 (73.0-91.0)
Hip circumference (cm) 104.0 (97.0-110.5) 101.0 (96-109.5) 99.0 (94.0-110.0) b 105.0 (100.0-
110.5)
101.0 (95.0-
107.8)
Wrist circumference (cm) 15.5 (15.0-16.5) 15.5 (15.0-16.2) 15.2 (14.5-16.0) 15.8 (15.2-16.5) 15.5 (15.0-16.2)
Systolic Blood Pressure (mmHg) 102.5 (98.0-111.3) 100.0 (90.3-112.3) 106.0 (98.0-112.3) 106.5 (98.3-116.8) 106.0 (98.0-
114.0)
Diastolic Blood Pressure (mmHg) 70.0 (65.0-75.0) 70.0 (68.8-81.3) 72.0 (68.8-81.3) 71.5 (65.0-77.0) 71.0 (64.0-76.0)
FBS 87.0 (81.5-91.5) 101.0 (96.0-109.5) 86.0 (81.0-89.0) 87.0 (81.3-95.0) 86.0 (81.0-92.0)
TT a 0.5 (0.3-0.7) 0.5 (0.4-0.8) c 0.4 (0.3-0.8) d 0.3 (0.2-0.4) 0.4 (0.2-0.6)
SHBG b, e 37.0 (27.0-
43.0)
b, f 58.0 (46.0-106.0) 36.0 (25.0-41.0) b, d 38.0 (28.0-
45.0)
45.5 (39.0-54.8)
FAI a, b, e 3.4 (2.2-
3.8)
f 2.1 (2.0-4.4) c 5.1 (3.2-7.7) 2.4 (1.9-3.6) 2.4 (1.5-4.2)
DHEAS 119.0 (77.0-162.3) 122.0 (85.7-139.2) c 180.0 (123.0-
221.8)
96.0 (64.0-130.0) 124.0 (75.5-
145.3)
A4 b 1.4 (0.6-2.3) 1.1 (0.3-1.4) 1.5 (0.9-2.7) 1.1 (0.5-1.6) 0.8 (0.5-1.7)
PCOS, polycystic ovary syndrome using NIH definition; CH, clinical hyperandrogenism; BH, biochemical hyperandrogenemia; IH, idiopathic hirsutism; Normal
group, eumenorrheic without hirsutism. BMI, body mass index; DHEAS, Dehydroepiandrosterone sulfate; Total T, Total testosterone; A4, Androstendion; SHBG, Sex
Hormone Binding Globulin; FAI, Free androgen index
Values are given as median (Inter quartile range), a = Group 1 vs. Group 4; b = vs. normal group, p < 0.001, c = Group 3 vs. Group 4, p < 0.001; d = Group 2 vs.
Group 4, p < 0.001; e = Group1 vs. Group 2, p < 0.001; f = Group 2 vs. Group 3, p < 0.001
The hormonal profile of women on hormonal therapy (n = 31) were excluded from statistical analysis.
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women with regular and predictable menstrual cycles or
should the serum concentration of all types of andro-
gens be universally measured to identify those women
with sub clinical hyperandrogenemia. The study proto-
col for screening of PCOS criteria at the community
level has a great impact on the PCOS prevalence esti-
mated. We did not measure the mid luteal phase serum
progesterone or androgens for those women has neither
hirsutism nor clinical menstrual dysfunction in their
first clinical assessment. It has been shown that 3.7% of
eumenorrheic, non hirsute women have oligo-ovulatory
cycles diagnosed by serum concentration of progester-
one [31]; therefore the number of women with men-
strual dysfunction in our study might have been
increased from 78 to 105 [(78 + (718 × 3.7%)] had we
assessed mid luteal phase serum progesterone of all par-
ticipants. To verify hyperandrogenemia, we measured
serum concentration of all types of androgens among
those women with either clinical menstrual dysfunction
or hirsutism but it has been shown 5.4% of women with
BH would have remain undiagnosed had we not
assessed the serum concentrations of androgens, regard-
less of regularity of their menstrual cycles [5].
The reported prevalence of idiopathic hirsutism varies
between 5-20% [1,5,16,41-43], being 13.0%(12.8%-13.2%)
in the present study. There are significant racial varia-
tion in prevalence of IH; East Asians are typically less
hairy than Euro-Americans, which may be explained by
low levels of 5a-reductase activity in the skin of those
women [27]. It has been reported that 50-70% of all hir-
sute women demonstrate regular menses, suggestive of
IH[1]; in our study 80%(205/256) of hirsute women had
regular and predictable menses; among them the anovu-
latory cycle of 22 women(11.3%) would possibly have
been overlooked had we did not measured the mid
luteal phase serum concentration of progesterone. In
the present study, 130 women had IH; these women
cannot be entirely excluded from the diagnosis of PCOS
and undoubtedly using the Rotterdam criteria will
further reduce this number [2]. However the appropri-
ateness of applying the Rotterdam criteria have been cri-
ticized and the additional phenotypes which are
d i a g n o s e da sP C O Sb yt h i sc r i t e r i ah a v eg i v e nr i s et o
considerable debate in recent literature [44]; it is essen-
tial to clearly identify the impact of adding these pheno-
types in research, clinical practice and also quality of life
of those women who may have been prematurely
labeled as having PCOS.
We excluded women with natural or surgical meno-
pause; however it is unlikely that our results were influ-
enced by not including those women. While the
incidence of uterine leiomyomata was 65% higher
among women with PCOS, than in those without the
condition [45] and women with PCOS were more often
hysterectomized [46], however the majorities of hyster-
ectomies are conducted among women above our age
limit(45 y). It has been shown that the natural age at
menopause in PCOS women is higher compared with
normo-ovulatory controls [47]. Since the mean age at
natural menopause was 50.4 years (S.D. = 4.3) for the
general population of Iranian women in a large national
survey [48],(much higher than our age limit), our esti-
mation is possibly not affected by excluding the meno-
pausal women. With ageing the clinical manifestations
of PCOS change and its reproductive abnormalities
decrease along with increase of its metabolic manifesta-
tions; as a result our estimations are not generalizable to
postmenopausal women.
The main strength of the present study is its metho-
dology as it is a community-based prevalence study on a
primarily ethnically homogeneous population with a
response rate of more than 90%. There few communities
based PCOS prevalence studies documented, because of
logistical problems in performing such investigations in
a large sample in a community setting. The amount of
intra-assay variability in our data is also likely to be
minimal because all the laboratory measurements were
done at the same laboratory by the same person.
Our study does have some limitations; we did not
consider vaginal ultrasonography and as a result could
not provide estimations using any definition other than
the NIH one. If the Rotterdam criteria were used and
polycystic ovaries had been seen on scan, some women
that were classified as “IH” would possibly reclassified as
“PCOS” and some participants that previously belonged
to either the “pure hyperandrogenism” or “pure men-
strual dysfunction” groups, would have been diagnosed
as PCOS using Rotterdam criteria. Our results may be
underestimates as the androgens and mid luteal serum
progesterone measurements were not evaluated for
those non hirsute women with regular and predictable
menstrual cycles; however it has been shown that only
3.7% of eumenorrheic women had anovulation [31].
Hence, it is likely that only a few women with PCOS
under NIH criteria were present in the population of
eumenorrheic non hirsute women.
Conclusion
These data from a large community based study confirm
the concept that PCOS and IH are the two most com-
mon gynecological endocrinopathies among reproduc-
tive aged women and the estimated prevalence of these
conditions is highly influenced by their screening meth-
ods for identification of the milder and subclinical phe-
notypes at the community level. A universal strategy for
screening of PCOS at the community level needs to be
developed for improving the comparability and
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spread screening of mild and sub clinical phenotypes of
PCOS have to be justified.
Acknowledgements
We thank the study participants for the substantial time and effort that each
contributed to this study. Acknowledgments are also due to research staff at
the Tehran Lipid and Glucose Study Unit and the staff in the Research
Endocrine Laboratory. Our special thanks to Dr. M. Hedayati for his
important contribution on hormonal and biochemical testing and to Mrs.
N. Shiva for editing the manuscript. We also thank the National Council of
Scientific Research of the Islamic Republic of Iran for approval of the Tehran
Lipid and Glucose Study project and its funding as a national research
project.
Author details
1Reproductive Endocrinology Research Center, Research Institute for
Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran,
Iran.
2Diabetes Research Center, Ahvaz Jundishapur University of Medical
Sciences, Tehran, Iran.
3Endocrine Research Center, Research Institute for
Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran,
Iran.
Authors’ contributions
FRT participated in the design of the study, performed the statistical analysis
and drafted the manuscript. HR participated in the coordination of the study
and helped to draft the manuscript. FA participated in the design of the
study and helped to draft the manuscript. All authors read and approved
the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 17 August 2011 Accepted: 1 November 2011
Published: 1 November 2011
References
1. Azziz R, Carmina E, Sawaya ME: Idiopathic hirsutism. Endocr Rev 2000,
21:347-362.
2. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF,
Futterweit W, Janssen OE, Legro RS, Norman RJ, Taylor AE, Witchel SF: The
Androgen Excess and PCOS Society criteria for the polycystic ovary
syndrome: the complete task force report. Fertil Steril 2009, 91:456-488.
3. Asuncion M, Calvo RM, San Millan JL, Sancho J, Avila S, Escobar-
Morreale HF: A prospective study of the prevalence of the polycystic
ovary syndrome in unselected Caucasian women from Spain. J Clin
Endocrinol Metab 2000, 85:2434-2438.
4. March WA, Moore VM, Willson KJ, Phillips DI, Norman RJ, Davies MJ: The
prevalence of polycystic ovary syndrome in a community sample
assessed under contrasting diagnostic criteria. Hum Reprod 2010,
25:544-551.
5. Tehrani FR, Simbar M, Tohidi M, Hosseinpanah F, Azizi F: The prevalence of
polycystic ovary syndrome in a community sample of Iranian
population: Iranian PCOS prevalence study. Reprod Biol Endocrinol 2011,
9:39.
6. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO: The
prevalence and features of the polycystic ovary syndrome in an
unselected population. J Clin Endocrinol Metab 2004, 89:2745-2749.
7. Mehrabian F, Khani B, Kelishadi R, Ghanbari E: The prevalence of polycystic
ovary syndrome in Iranian women based on different diagnostic criteria.
Endokrynol Pol 2011, 62:238-242.
8. Chen X, Yang D, Mo Y, Li L, Chen Y, Huang Y: Prevalence of polycystic
ovary syndrome in unselected women from southern China. Eur J Obstet
Gynecol Reprod Biol 2008, 139:59-64.
9. Goodarzi MO, Quinones MJ, Azziz R, Rotter JI, Hsueh WA, Yang H:
Polycystic ovary syndrome in Mexican-Americans: prevalence and
association with the severity of insulin resistance. Fertil Steril 2005,
84:766-769.
10. Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR, Azziz R:
Prevalence of the polycystic ovary syndrome in unselected black and
white women of the southeastern United States: a prospective study. J
Clin Endocrinol Metab 1998, 83:3078-3082.
11. Michelmore KF, Balen AH, Dunger DB, Vessey MP: Polycystic ovaries and
associated clinical and biochemical features in young women. Clin
Endocrinol (Oxf) 1999, 51:779-786.
12. Diamanti-Kandarakis E, Kouli CR, Bergiele AT, Filandra FA, Tsianateli TC,
Spina GG, Zapanti ED, Bartzis MI: A survey of the polycystic ovary
syndrome in the Greek island of Lesbos: hormonal and metabolic
profile. J Clin Endocrinol Metab 1999, 84:4006-4011.
13. Farah L, Lazenby AJ, Boots LR, Azziz R: Prevalence of polycystic ovary
syndrome in women seeking treatment from community electrologists.
Alabama Professional Electrology Association Study Group. J Reprod Med
1999, 44:870-874.
14. Moran C, Tena G, Moran S, Ruiz P, Reyna R, Duque X: Prevalence of
polycystic ovary syndrome and related disorders in mexican women.
Gynecol Obstet Invest 2010, 69:274-280.
15. Ansarin H, Aziz-Jalali MH, Rasi A, Soltani-Arabshahi R: Clinical presentation
and etiologic factors of hirsutism in premenopausal Iranian women. Arch
Iran Med 2007, 10:7-13.
16. Azziz R, Waggoner WT, Ochoa T, Knochenhauer ES, Boots LR: Idiopathic
hirsutism: an uncommon cause of hirsutism in Alabama. Fertil Steril 1998,
70:274-278.
17. Barbieri RL: Hyperandrogenic disorders. Clin Obstet Gynecol 1990,
33:640-654.
18. Christakou CD, Diamanti-Kandarakis E: Role of androgen excess on
metabolic aberrations and cardiovascular risk in women with polycystic
ovary syndrome. Womens Health (Lond Engl) 2008, 4:583-594.
19. Chun-Sen H, Chien-Hua W, Wan-Chun C, Ching-Tzu L, Chun-Jen C, Ming IH:
Obesity and insulin resistance in women with polycystic ovary
syndrome. Gynecol Endocrinol 2011, 5:300-306.
20. Talbott EO, Zborowski JV, Rager JR, Boudreaux MY, Edmundowicz DA,
Guzick DS: Evidence for an association between metabolic cardiovascular
syndrome and coronary and aortic calcification among women with
polycystic ovary syndrome. J Clin Endocrinol Metab 2004, 89:5454-5461.
21. Zhang HY, Zhu FF, Xiong J, Shi XB, Fu SX: Characteristics of different
phenotypes of polycystic ovary syndrome based on the Rotterdam
criteria in a large-scale Chinese population. BJOG 2009, 116:1633-1639.
22. El-Mazny A, Abou-Salem N, El-Sherbiny W: Insulin resistance, dyslipidemia,
and metabolic syndrome in women with polycystic ovary syndrome. Int
J Gynaecol Obstet 2010, 109:239-241.
23. Abdel Fattah NS, Darwish YW: Is there a role for insulin resistance in
nonobese patients with idiopathic hirsutism? Br J Dermatol 2009,
160:1011-1015.
24. Norman RJ, Mahabeer S, Masters S: Ethnic differences in insulin and
glucose response to glucose between white and Indian women with
polycystic ovary syndrome. Fertil Steril 1995, 63:58-62.
25. Dunaif A, Sorbara L, Delson R, Green G: Ethnicity and polycystic ovary
syndrome are associated with independent and additive decreases in
insulin action in Caribbean-Hispanic women. Diabetes 1993, 42:1462-1468.
26. DeUgarte CM, Woods KS, Bartolucci AA, Azziz R: Degree of facial and body
terminal hair growth in unselected black and white women: toward a
populational definition of hirsutism. J Clin Endocrinol Metab 2006,
91:1345-1350.
27. Lookingbill DP, Demers LM, Wang C, Leung A, Rittmaster RS, Santen RJ:
Clinical and biochemical parameters of androgen action in normal
healthy Caucasian versus Chinese subjects. J Clin Endocrinol Metab 1991,
72:1242-1248.
28. Kumarapeli V, Seneviratne Rde A, Wijeyaratne CN, Yapa RM,
Dodampahala SH: A simple screening approach for assessing community
prevalence and phenotype of polycystic ovary syndrome in a semi-
urban population in Sri Lanka. Am J Epidemiol 2008, 168:321-328.
29. Hsu MI, Liou TH, Chou SY, Chang CY, Hsu CS: Diagnostic criteria for
polycystic ovary syndrome in Taiwanese Chinese women: comparison
between Rotterdam 2003 and NIH 1990. Fertil Steril 2007, 88:727-729.
30. Hatch R, Rosenfield RL, Kim MH, Tredway D: Hirsutism: implications,
etiology, and management. Am J Obstet Gynecol 1981, 140:815-830.
31. Malcolm CE, Cumming DC: Does anovulation exist in eumenorrheic
women? Obstet Gynecol 2003, 102:317-318.
Tehrani et al. Reproductive Biology and Endocrinology 2011, 9:144
http://www.rbej.com/content/9/1/144
Page 7 of 832. Mehta A, Matwijiw I, Taylor PJ, Salamon EA, Kredentser JV, Faiman C:
Should androgen levels be measured in hirsute women with normal
menstrual cycles? Int J Fertil 1992, 37:354-357.
33. Azizi F, Rahmani M, Ghanbarian A, Emami H, Salehi P, Mirmiran P, Sarbazi N:
Serum lipid levels in an Iranian adults population: Tehran Lipid and
Glucose Study. Eur J Epidemiol 2003, 18:311-319.
34. Chiazze L Jr, Brayer FT, Macisco JJ Jr, Parker MP, Duffy BJ: The length and
variability of the human menstrual cycle. JAMA 1968, 203:377-380.
35. Treloar AE, Boynton RE, Behn BG, Brown BW: Variation of the human
menstrual cycle through reproductive life. Int J Fertil 1967, 12:77-126.
36. Azziz R: PCOS: a diagnostic challenge. Reprod Biomed Online 2004,
8:644-648.
37. Barth JH, Yasmin E, Balen AH: The diagnosis of polycystic ovary
syndrome: the criteria are insufficiently robust for clinical research. Clin
Endocrinol (Oxf) 2007, 67:811-815.
38. Broekmans FJ, Knauff EA, Valkenburg O, Laven JS, Eijkemans MJ, Fauser BC:
PCOS according to the Rotterdam consensus criteria: Change in
prevalence among WHO-II anovulation and association with metabolic
factors. BJOG 2006, 113:1210-1217.
39. Hull MG: Epidemiology of infertility and polycystic ovarian disease:
endocrinological and demographic studies. Gynecol Endocrinol 1987,
1:235-245.
40. Wijeyaratne CN, Balen AH, Barth JH, Belchetz PE: Clinical manifestations
and insulin resistance (IR) in polycystic ovary syndrome (PCOS) among
South Asians and Caucasians: is there a difference? Clin Endocrinol (Oxf)
2002, 57:343-350.
41. Carmina E: Prevalence of idiopathic hirsutism. Eur J Endocrinol 1998,
139:421-423.
42. Moran C, Tapia MC, Hernandez E, Vazquez G, Garcia-Hernandez E,
Bermudez JA: Etiological review of hirsutism in 250 patients. Arch Med
Res 1994, 25:311-314.
43. Carmina E, Rosato F, Janni A, Rizzo M, Longo RA: Extensive clinical
experience: relative prevalence of different androgen excess disorders in
950 women referred because of clinical hyperandrogenism. J Clin
Endocrinol Metab 2006, 91:2-6.
44. Azziz R: Controversy in clinical endocrinology: diagnosis of polycystic
ovarian syndrome: the Rotterdam criteria are premature. J Clin Endocrinol
Metab 2006, 91:781-785.
45. Wise LA, Palmer JR, Stewart EA, Rosenberg L: Polycystic ovary syndrome
and risk of uterine leiomyomata. Fertil Steril 2007, 87:1108-1115.
46. Dahlgren E, Johansson S, Lindstedt G, Knutsson F, Oden A, Janson PO,
Mattson LA, Crona N, Lundberg PA: Women with polycystic ovary
syndrome wedge resected in 1956 to 1965: a long-term follow-up
focusing on natural history and circulating hormones. Fertil Steril 1992,
57:505-513.
47. Laven JS, Mulders AG, Visser JA, Themmen AP, De Jong FH, Fauser BC: Anti-
Mullerian hormone serum concentrations in normoovulatory and
anovulatory women of reproductive age. J Clin Endocrinol Metab 2004,
89:318-323.
48. Mohammad K, Sadat Hashemi SM, Farahani FK: Age at natural menopause
in Iran. Maturitas 2004, 49:321-326.
doi:10.1186/1477-7827-9-144
Cite this article as: Tehrani et al.: The prevalence of idiopathic hirsutism
and polycystic ovary syndrome in the Tehran Lipid and Glucose Study.
Reproductive Biology and Endocrinology 2011 9:144.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Tehrani et al. Reproductive Biology and Endocrinology 2011, 9:144
http://www.rbej.com/content/9/1/144
Page 8 of 8